Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Clinical Study of MHB036C for Injection Combined With MHB039A for Injection in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

NCT07130383 is registered in ClinicalTrials.gov with Minghui Pharmaceutical (Hangzhou) Ltd as lead sponsor.

NCT NCT07130383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07130383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Clinical Study of MHB036C for Injection Combined With MHB039A for Injection in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2025
Completion date
August 31, 2031
Enrollment
210 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced malignant solid tumor